What is Antengene?
Antengene is a leading commercial-stage biopharmaceutical firm dedicated to the development of first-in-class and best-in-class therapeutic medicines for cancer and other life-threatening conditions. Operating under the vision of Treating Patients Beyond Borders, the company leverages a dual-engine strategy that combines in-house drug discovery with strategic global partnerships. This approach has yielded a diverse portfolio of 15 clinical and pre-clinical assets, positioning Antengene as a critical player in the international oncology market. By focusing on high-potential therapeutic areas, the firm effectively bridges the gap between innovative research and patient access in key markets including China, South Korea, Singapore, and Australia.
How much funding has Antengene raised?
Antengene has raised a total of $238M across 3 funding rounds:
Series A
$21M
Series B
$120M
Series C
$97M
Series A (2017): $21M with participation from TF Capital, Qiming Venture Partners, Huagai Capital, and Tigermed
Series B (2019): $120M led by Boyu Capital
Series C (2020): $97M supported by GL Ventures, Fidelity Management & Research Company, GIC, Qiming Venture Partners, and Boyu Capital
Key Investors in Antengene
Fidelity Management & Research Company
Fidelity Investments is a financial services company that provides a broad range of investment, wealth management, retirement planning, brokerage, and advisory solutions for individual investors, businesses, employers, and institutions.
GIC
Founded in 1981, GIC is a sovereign wealth fund that manages Singapore's foreign reserves by investing across a range of asset classes in both the public and private markets.
Boyu Capital
Boyu is a leading alternative asset management firm specializing in private equity, venture capital, and healthcare sectors, providing catalytic capital to high-potential businesses.
What's next for Antengene?
With the support of its latest capital infusion, Antengene is poised to scale its commercial operations and further expand its clinical development footprint. The company's strategic roadmap emphasizes the acceleration of its late-stage pipeline, with a focus on securing additional new drug application approvals in diverse geographic territories. As Antengene continues to leverage its existing partnerships and internal R&D capabilities, the firm is well-positioned to enhance its market share in the competitive anti-cancer drug sector. Future growth will likely be driven by the continued commercialization of its flagship products and the advancement of its next-generation therapeutic candidates, ensuring long-term value creation for stakeholders and improved outcomes for patients globally.
See full Antengene company page
